The analysis of medical prescriptions for patients with duodenal ulcer in hospital setting
DOI:
https://doi.org/10.24959/sphhcj.24.311Keywords:
duodenal ulcer; treatment protocol; medicines; monitoring of medical prescriptionsAbstract
Aim. To analyze medical prescriptions for patients with duodenal ulcer disease in hospital setting, to determine the compliance of the treatment with the current treatment protocols.
Materials and methods. We used 102 case histories, medical prescriptions of the Gastroenterology Department of the Clinical Regional Hospital named after M.I. Pirogov, Unified Clinical Protocol of the primary and specialized medical care “Peptic ulcer of the stomach and duodenum in adults and children”, the State Formulary of Medicines of Ukraine, the nomenclature of drugs for the treatment of duodenal ulcer, the official online resource tabletki.ua. Statistical, analytical and comparative, systematic, logical, graphic and mathematical-statistical methods were applied.
Results and discussion. As a result of the study conducted, an analysis of drug prescriptions for patients with duodenal ulcer was carried out at the premises of the Gastroenterology Department of the Clinical Regional Hospital named after M. I. Pirogov. Over a period of 1 year and 3 months, 102 patients with the main diagnosis of duodenal ulcer were treated. According to the data obtained from the histories of diseases, men (94 %) aged 30-40 years were most often ill. The average duration of bed days was 5 days. The most common concomitant diseases were pancreatitis, GERD (non-erosive, endoscopically positive), hepatitis, duodenal bile reflux, Oddi sphincter dysfunction (pancreatic type). Two groups of drugs were prescribed according to the ATC classification for pathogenetic and symptomatic treatment: group A – drugs affecting the digestive system and metabolism (71.43 %) and group J – antimicrobial drugs for systemic use (28.57 %). Among the producing countries, foreign-made drugs prevailed – 62.4 %. During the study period, doctors prescribed 63 active substances by INN and 109 drugs by TN. In accordance with the Unified Clinical Protocol, the number of INN drugs was 18, 39 drugs by TN, and the State Formulary included drugs of 48 INN and 80 TN. During the study period, 24 drugs by TN for the pathogenetic treatment (eradication therapy) and 18 drugs by TN for the symptomatic treatment were prescribed. The prescription of drugs for the pathogenetic and symptomatic treatment was scientifically substantiated and included in the current normative documentation for the provision of patients with duodenal ulcer. When conducting the eradication therapy the leading drugs were Omeprazole (66 prescriptions), De-nol (55 prescriptions), Ezonexa (29 prescriptions), Controlok (26 prescriptions), Pilobact Neo (24 prescriptions). To prevent dysbiosis, such drugs as Enterol (8 prescriptions), Enterogermina forte (7 prescriptions) were most often prescribed. To relieve the symptoms of duodenal ulcer, Mebsyn Retard (24 prescriptions), Trimspa (19 prescriptions), Neospastil (17 prescriptions) were applied.
Conclusions. Therefore, the medical care of patients in hospital setting is expedient and corresponds to the current Treatment Protocols.
References
Khimion, L. V., Yashchenko, O. B., Danyliuk, S. V., Sytiuk, T. O. (2018). Suchasni pidkhody do diahnostyky ta vedennia khvorykh na vyrazkovu khvorobu shlunku ta dvanadtsiatypaloi kyshky na pervynnomu rivni medychnoi dopomohy. Semeinaia medytsyna, 1 (75), 6-12.
Kniazkova, I. I. Vyrazkova khvoroba shlunka ta dvanadtsiatypaloi kyshky: aspekty diahnostyky. Available at: https://health-ua.com/article/62210-virazkova-hvoroba-shlunka--ta-dvanadtcyatipalo-kishki--aspekti-dagnostiki.
Sonnenberg, A., Turner, K. O., Genta, R. M. (2020). Low Prevalence of Helicobacter pylori-Positive Peptic Ulcers in Private Outpatient Endoscopy Centers in the United States. Am J Gastroenterol, 115(2), 244-250. doi: 10.14309/ajg.0000000000000517
Huang, J.-Q., Sridhar, S., Hunt, R. H. (2002). Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet, 359 (9300), 14-22. doi: 10.1016/s0140-6736(02)07273-2
Krekoten, O. M., Chereshniuk, H. S. (2014). Dyspanseryzatsiia v diialnosti likaria ta medychnoho zakladu : navch. posib. Vinnytsia : Nilan-LTD.
Makarenko, O. V., Karimova, M. M., Masheiko, A. M. (2018). Kliniko-ekonomichnyi analiz likarskykh pryznachen ditiam ta pidlitkam, khvorym na Helicobacter pylory-asotsiiovanu hastroduodenalnu patolohiiu. Farmatsevtychnyi zhurnal, 5-6, 11-21.
Herasymova, O. O., Yaovlieva, L. V., Yakymenko, A. I. (2020). Otsinka dotsilnosti likarskykh pryznachen patsiientam z peptychnoiu vyrazkoiu shlunku v realnii klinichnii praktytsi. Acta Medica Leopoliensia, 26, 4. doi: 10.25040/aml2020.04.039
Herasymova, O. O., Krasiuk, A. A. (2017). Analiz asortymentu LZ, shcho vykorystovuiutsia v skhemakh antykhelikobakternoi terapii, na farmatsevtychnomu rynku Ukrainy. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 2 (50), 54-62. doi:10.22141/2224-0551.17.5.2022.1522.
Pro zatverdzhennia Unifikovanoho klinichnoho protokolu pervynnoi ta spetsializovanoi medychnoi dopomohy “Peptychna vyrazka shlunka ta dvanadtsiatypaloi kyshky u doroslykh i ditei” : nakaz No. 1514 vid 25.08.2023. Available at: https://zakon.rada.gov.ua/rada/show/v1514282-23#Text.
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: https://moz.gov.ua/derzhavnij-reestr-likarskih-zasobiv-ukraini.
Derzhavnyi formuliar likarskykh zasobiv Ukrainy. Available at: https://www.dec.gov.ua/materials/chinnij-vipusk-derzhavnogo-formulyara-likarskih-zasobiv.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).